Drugs / Talacotuzumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02920424 | Jun 2017 → Feb 2019 | systemic lupus erythematosus | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT01632852 | Jul 2012 → Aug 2015 | acute myeloid leukemia | CSL Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03011034 | Feb 2017 → Jan 2019 | myelodysplastic syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02992860 | Jul 2016 → Oct 2018 | acute myeloid leukemia, myelodysplastic syndrome | GWT-TUD GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02472145 | Aug 2015 → Jan 2018 | acute myeloid leukemia | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talacotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02472145 ↗ |
| Known as | CSL362 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632852 ↗ |
| Known as | JNJ-56022473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02920424 ↗ |
| Modality | Monoclonal antibody | “CSL362 is humanized monoclonal antibody” NCT01632852 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT01632852 ↗ |
| Target | IL3RA | “CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123)” NCT01632852 ↗ |